Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学TIL Therapy, Cancer Immunotherapy Pioneer

Steven Rosenberg

MD

🏢National Cancer Institute🌐USA

Chief, Surgery Branch

128
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Steven Rosenberg at NCI is the father of modern cancer immunotherapy, having pioneered high-dose interleukin-2, tumor-infiltrating lymphocyte (TIL) therapy, and adoptive T cell transfer as cancer treatments since the 1970s. His seminal clinical demonstrations that T cells can destroy established tumors inspired the entire field of cancer immunotherapy. The first FDA-approved TIL therapy (lifileucel) for melanoma was derived directly from decades of his foundational work.

Share:

🧪Research Fields 研究领域

tumor-infiltrating lymphocytes
IL-2 immunotherapy
adoptive cell therapy
cancer immunotherapy history
TIL lifileucel

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-02-01 | All information from publicly available academic sources

关注 Steven Rosenberg 的研究动态

Follow Steven Rosenberg's research updates

留下邮箱,当我们发布与 Steven Rosenberg(National Cancer Institute)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment